Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…Abstract Number: 1658 • 2018 ACR/ARHP Annual Meeting
Which Factors Influence the Diagnostic Delay in Patients with Axial Spondyloarthritis?
Background/Purpose: The interval from symptom onset till diagnosis in axial spondyloarthritis (axSpA) was reported a decade ago to be between five and ten years. The…Abstract Number: 661 • 2018 ACR/ARHP Annual Meeting
Bridging the Gap between Symptom Onset and Diagnosis in Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is diagnosed an average of 9 years after symptom onset (1), partly because inflammatory back pain (IBP) can be difficult…Abstract Number: 1864 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
Background/Purpose: COAST-V (NCT02696785) is the first phase 3 study of ixekizumab (IXE), a high-affinity anti-IL-17A monoclonal antibody, in patients (pts) with active radiographic axial SpA…Abstract Number: 666 • 2018 ACR/ARHP Annual Meeting
Inflammation on MRI of the Sacroiliac Joints Is Highly Associated with Structural Damage in Axial Spondyloarthritis Patients in Clinical Practice: Data from the ASAS and DESIR Cohorts
Background/Purpose: The effect of MRI-detected inflammation on the development of radiographic damage at the sacroiliac joints (SIJ) level in patients (pts) with axial SpA (axSpA)…Abstract Number: 1867 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network…Abstract Number: 675 • 2018 ACR/ARHP Annual Meeting
Quantitative Ultrasound of the Calcaneus Has a Role to Play in Detecting Low Bone Mineral Density in Axial Spondyloarthropathy Patients
Background/Purpose: Axial spondyloarthropathy (axSpA) patients have an increased risk of developing osteoporosis compared to matched controls. Dual energy x-ray absorptiometry (DXA) is the technique of…Abstract Number: 1868 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)
Background/Purpose: In the USA, certolizumab pegol (CZP) is approved for treatment of adults with active ankylosing spondylitis (AS) and not for non-radiographic axial spondyloarthritis (nr-axSpA).…Abstract Number: 678 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?
Background/Purpose: Along with emergence of the term of ‘non-radiographic axial SpA’ (nr-AxSpA), studies comparing AS and nr-AxSpA in terms of genetic, epidemiologic, and clinical issues…Abstract Number: 2062 • 2018 ACR/ARHP Annual Meeting
Omentin-1: Potential Biomarker of Cardiovascular Risk in Axial Spondyloarthritis? a Serological and Genetic Study
Background/Purpose: Cardiovascular (CV) disease (mainly due to accelerated atherosclerosis) is one of the main causes of mortality in axial spondyloarthritis (axSpA). The higher incidence of…Abstract Number: 691 • 2018 ACR/ARHP Annual Meeting
A Service Evaluation of Reporting Standards of Computer Tomography Defined Sacroiliitis Suggestive of Axial Spondyloarthritis in Inflammatory Bowel Disease Patients Imaged for Non-Musculoskeletal Indications
Background/Purpose: A combined service evaluation by the rheumatology and radiology department was undertaken to understand the frequency and reporting standards of Computer Tomography-defined Sacroiliitis (CTSI)…Abstract Number: 2076 • 2018 ACR/ARHP Annual Meeting
Transmembrane TNF (tmTNF) Transgenic Mice Exhibit Enlarged Lymph Nodes and Elevated Numbers of High Endothelial Cells Associated with Increased Lymphocyte Recruitment
Background/Purpose: The NF-κB family of transcription factors plays a crucial role in chronic inflammatory diseases and can be activated via two distinct pathways. Non-canonical NF-κB…Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…Abstract Number: 2133 • 2018 ACR/ARHP Annual Meeting
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are 3 common inflammatory rheumatic diseases that can lead to deformities and joint destruction;…Abstract Number: 893 • 2018 ACR/ARHP Annual Meeting
Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods
Background/Purpose: Big data research in axial spondyloarthritis (axSpA) is limited by a lack of adequate methods for identifying axSpA patients, since there are no billing…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 16
- Next Page »